Reproducible outcomes are a proven part of XIENCE™ DES performance, delivering consistent patient safety with low complication rates. As a result, XIENCE™ Stent can treat lesions of any complexity in patients with a range of challenging comorbidities1
Complex lesions and increasingly complex percutaneous coronary intervention (PCI) cases compose an ever-growing segment of the patient population, and stenting for these populations may expand in the future.
Even when patients are complex, choosing a stent shouldn't be. Given the best-in-class deliverability2 and the expanded treatment options3 of XIENCE Sierra™ this stent is an excellent choice for complex patients.4-7
XIENCE™ Stent, the world’s leading DES, is considered by industry experts to be the gold standard.8 It offers unmatched consistency and optimal acute outcomes in all types of patients and lesions, including complex cases.9,10
Results from a number of multicenter, randomized trials show that XIENCE™ Stent has low stent thrombosis (ST) rates, from 30 days to 5 years.
* DAPT duration of 1 month
In a meta-analysis of all-comer complex patients, XIENCE™ Stent was shown to save lives compared to bare metal stents (BMS).17
Fatal Myocardial Infarction
Primary Endpoint: Cardiac Death
|Myocardial Infarction||BMS (%)||DES (%)||p value (non-adjusted)||p value (†adjusted)|
†Adjusted for clinical syndrome (ie, acute coronary syndrome vs stable syndrome), history of diabetes mellitus, female sex, use of glycoprotein IIb/IIIa inhibitors, and up to 1 year vs longer duration of DAPT.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?